Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Organogenesis Holdings (ORGO) EBITDA Margin (2017 - 2025)

Historic EBITDA Margin for Organogenesis Holdings (ORGO) over the last 9 years, with Q3 2025 value amounting to 13.74%.

  • Organogenesis Holdings' EBITDA Margin rose 83200.0% to 13.74% in Q3 2025 from the same period last year, while for Sep 2025 it was 1.8%, marking a year-over-year increase of 10100.0%. This contributed to the annual value of 0.27% for FY2024, which is 31600.0% down from last year.
  • According to the latest figures from Q3 2025, Organogenesis Holdings' EBITDA Margin is 13.74%, which was up 83200.0% from 12.45% recorded in Q2 2025.
  • In the past 5 years, Organogenesis Holdings' EBITDA Margin registered a high of 19.15% during Q2 2021, and its lowest value of 30.85% during Q1 2025.
  • In the last 5 years, Organogenesis Holdings' EBITDA Margin had a median value of 7.42% in 2023 and averaged 3.18%.
  • As far as peak fluctuations go, Organogenesis Holdings' EBITDA Margin soared by 367400bps in 2021, and later crashed by -273500bps in 2025.
  • Over the past 5 years, Organogenesis Holdings' EBITDA Margin (Quarter) stood at 15.45% in 2021, then tumbled by -51bps to 7.55% in 2022, then plummeted by -117bps to 1.27% in 2023, then skyrocketed by 734bps to 8.07% in 2024, then skyrocketed by 70bps to 13.74% in 2025.
  • Its EBITDA Margin was 13.74% in Q3 2025, compared to 12.45% in Q2 2025 and 30.85% in Q1 2025.